TW-37 化学構造
分子量: 573.7

高品質保証

カスタマーフィードバック(7)

MSDS

製品説明

  • Compare Bcl-2 Inhibitors
    Bcl-2製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 TW-37は一種の新たな非ペプチド類阻害剤で、無細胞試験で、組替えのBcl-2、Bcl-xLとMcl-1に作用する時のKi値が0.29μM、1.11μMと0.26μMにそれぞれ分かれることです。
ターゲット Bcl-2 Bcl-xL Mcl-1
IC50 0.29 μM (Ki) 1.11 μM (Ki) 0.26 μM (Ki) [1]
In vitro試験 TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]
In vivo試験 TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]
臨床試験 TW-37 is currently in Phase I/II clinical trials in patients with Chronic Lymphocytic Leukemia.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].

細胞アッセイ: [2]

細胞株 HDMECs
濃度 0 - 100 μM
反応時間 96 hours
実験の流れ The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments

動物実験: [3]

動物モデル Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
製剤 TW-37 is resuspended in 1:1 Tween 80/ethanol (diluted 10-fold in 0.9% saline before use).
投薬量 ~40 mg/kg
投与方法 Administered via i.v. or i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download TW-37 SDF
分子量 573.7
化学式

C33H35NO6S

CAS No. 877877-35-5
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 5-(2-isopropylbenzyl)-N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxybenzamide

文献中の引用 (13)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477は一種の有効で、選択性的なMCL-1阻害剤で、 Ki値とIC50値が0.454 nMと26.2 nMに分かれることですが、MCL-1に作用する選択性は他のBcl-2家族メンバーに作用する選択性より100倍以上が高くなります。

  • MI-773 (SAR405838)

    MI-773 (SAR405838)は一種の経口生物利用可能なMDM2拮抗剤で、Ki値が0.88 nMです。臨床1期。

  • Navitoclax (ABT-263)

    Navitoclax (ABT-263)は一種の有効なBcl-xL、Bcl-2とBcl-w阻害剤で、無細胞試験でKi値が0.5 nM及び0.5 nM以下、1nM及び1nM以下と1nM及び1nM以下にそれぞれ分かれることですが、Mcl-1、A1と結合する作用が少し弱いです。臨床2期。

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199)は一種の選択性的なBcl-2阻害剤で、無細胞試験でKi値が0.01 nM以下ですが、Bcl-2に作用する選択性はBcl-xLとBcl-wに作用する選択性より4800倍以上が高くなって、Mcl-1を抑制する活性がありません。臨床3期。

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737は一種のBH3模倣の阻害剤で、無細胞試験でBcl-xL、Bcl-2とBcl-wに作用する時のEC50値が78.7 nM、30.3 nMと197.8 nMにそれぞれ分かれることですが、Mcl-1、Bcl-BとBfl-1を抑制する作用がありません。臨床2期。

  • UMI-77

    UMI-77は一種の選択性的なMcl-1阻害剤で、Ki値が490 nMですが、Mcl-1に作用する選択性はBcl-2家族他のメンバ-に作用する選択性より高いです。

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は一種のBcl-2拮抗剤で、無細胞試験でKi値が0.22μMですし、MCL-1が媒介した抗アポトーシス作用を抑制することに協力します。臨床3期。

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • Sabutoclax

    Sabutoclaxは一種のpan-Bcl-2阻害剤で、Bcl-xL、Bcl-2、Mcl-1とBfl-1に作用する時のIC50値が0.31μM、0.32μM、0.20μMと0.62μMにそれぞれ分かれることです。

  • AT101

    AT101はゴシポール酢酸(Gossypol acetic acid)のR-(-)エナンチオマー(enantiomer)で、無細胞試験でBcl-2、Bcl-xLとMcl-1と結合する時のKi値が0.32μM、0.48μMと0.18μMにそれぞれ分かれることですが、BIR3ドメインとBIDを抑制しません。臨床2期。

最近チェックしたアイテム

Tags: TW-37を買う | TW-37供給者 | TW-37を購入する | TW-37費用 | TW-37生産者 | オーダーTW-37 | TW-37代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ